Using flow cytometry, we confirmed that EOL-1 cells differentiated into eosinophils in response to BA treatment; CCR3 and IL-5R were used as markers to confirm the differentiation of EOL-1 cells into eosinophils. The gene discussed is CCR3; the disease is breast angiosarcoma.